Literature DB >> 24116909

Developing siRNA therapies to address osteoporosis.

Yuwei Wang1, David W Grainger.   

Abstract

Osteoporosis is a skeletal system pathology characterized by low bone mineral density and tissue structural deterioration. This malady is associated with high fracture risk that severely compromises quality of life. Osteoporosis incidence is becoming more significant with increasing lifespan worldwide. However, current approaches for treating osteoporosis cannot and do not treat the disease in the most ideal manner for diverse reasons. Substantial research has sought both the discovery of new targets and new therapies. In this review, emerging possible RNAi-mediated therapeutic opportunities for osteoporosis are identified and associated challenges discussed. Targeted delivery strategies capable of more reliable and efficient delivery to skeletal tissue are described, as well as possibilities to treat bone-forming cells with siRNA to produce cell-based therapy.

Entities:  

Mesh:

Year:  2013        PMID: 24116909      PMCID: PMC3891929          DOI: 10.4155/tde.13.85

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  41 in total

1.  Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.

Authors:  Yuwei Wang; Alexandra Panasiuk; David W Grainger
Journal:  Mol Pharm       Date:  2011-01-21       Impact factor: 4.939

2.  Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.

Authors:  Frederic Morvan; Kim Boulukos; Philippe Clément-Lacroix; Sergio Roman Roman; Isabelle Suc-Royer; Béatrice Vayssière; Patrick Ammann; Patrick Martin; Sonia Pinho; Philippe Pognonec; Patrick Mollat; Christof Niehrs; Roland Baron; Georges Rawadi
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

3.  Cystamine-terminated poly(beta-amino ester)s for siRNA delivery to human mesenchymal stem cells and enhancement of osteogenic differentiation.

Authors:  Stephany Y Tzeng; Ben P Hung; Warren L Grayson; Jordan J Green
Journal:  Biomaterials       Date:  2012-08-04       Impact factor: 12.479

Review 4.  Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide.

Authors:  Federico Mosna; Luc Sensebé; Mauro Krampera
Journal:  Stem Cells Dev       Date:  2010-10       Impact factor: 3.272

5.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

6.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

7.  RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.

Authors:  Kumaran Sundaram; Riko Nishimura; Joseph Senn; Rimon F Youssef; Steven D London; Sakamuri V Reddy
Journal:  Exp Cell Res       Date:  2006-10-06       Impact factor: 3.905

8.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

9.  Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation.

Authors:  Hyeonju Yeo; Lauren H Beck; Jay M McDonald; Majd Zayzafoon
Journal:  Bone       Date:  2007-02-24       Impact factor: 4.398

10.  The Business of RNAi Therapeutics in 2012.

Authors:  Dirk Haussecker
Journal:  Mol Ther Nucleic Acids       Date:  2012-02-07       Impact factor: 10.183

View more
  4 in total

Review 1.  Small non-coding RNAs-based bone regulation and targeting therapeutic strategies.

Authors:  Ying Yang; Sijie Fang
Journal:  Mol Cell Endocrinol       Date:  2016-11-23       Impact factor: 4.102

2.  Integrative Analysis of Regulatory Module Reveals Associations of Microgravity with Dysfunctions of Multi-body Systems and Tumorigenesis.

Authors:  Mengqin Yuan; Haizhou Liu; Shunheng Zhou; Xu Zhou; Yu-E Huang; Fei Hou; Wei Jiang
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

Review 3.  Molecular Mechanisms and Emerging Therapeutics for Osteoporosis.

Authors:  Ji-Yoon Noh; Young Yang; Haiyoung Jung
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

4.  Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.

Authors:  Genc Basha; Mina Ordobadi; Wilder R Scott; Andrew Cottle; Yan Liu; Haitang Wang; Pieter R Cullis
Journal:  Mol Ther Nucleic Acids       Date:  2016-09-13       Impact factor: 10.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.